- Veri Yok
Türkçe
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
In the vigorous development of contemporary technology, green laser has become a shining star in the field of electronics. Not only because of its excellent performance, but also because it brings infinite imagination and creative inspiration to creators. The use of green laser for PCB (Printed Circuit Board) and FPC (Flexible Printed Circuit Board) shape cutting has opened up a new artistic journ...
Recently, a team led by researcher Zhaoyang Wei of the Precision Optics Manufacturing and Testing Center of the Shanghai Institute of Optics and Fine Mechanics, Chinese Academy of Sciences, has realized the manufacture of fused quartz components with high resistance to UV laser damage based on the defect characterization and removal process of CO2 laser. The research is published in Light: Advance...
Neptunium is the main radioactive component of nuclear waste, with a complex atomic structure that can be explored through mass spectrometry. This analysis is crucial for understanding its inherent characteristics and determining the isotopic composition of neptunium waste. Magdalena Kaja and her team from Johannes Gutenberg University in Mainz, Germany have developed a novel laser spectroscopy te...
Recently, the team led by Professor Li Zhiyuan from South China University of Technology has successfully developed a full spectrum white light laser, which has the characteristics of bright spot, smooth and flat spectrum, and large pulse energy. It can cover the ultraviolet visible infrared full spectrum of 300-5000nm, with a single pulse energy of 0.54mJ.The launch of such a full spectrum white ...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...